Cartesian Therapeutics, Inc. (RNAC) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -155.36M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 68.39M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-155.36M | $0.00 | (m) | $68.39M | (m) | (m) |
| 2026-03-31 | $-148.01M | $0.00 | (m) | $62.82M | (m) | (m) |
| 2025-12-31 | $-143.41M | $400.00K | (m) | $58.03M | (m) | -35851.25% |
| 2025-09-30 | $-91.50M | $-436.00K | (m) | $54.65M | (m) | 20985.55% |
| 2025-06-30 | $-88.01M | $-436.00K | (m) | $52.25M | (m) | 20184.86% |
| 2025-03-31 | $-52.44M | $32.84M | (m) | $50.04M | (m) | -159.70% |
| 2024-12-31 | $-43.90M | $38.27M | (m) | $45.10M | (m) | -114.69% |
| 2024-09-30 | $-53.50M | $47.38M | (m) | $56.23M | (m) | -112.92% |
| 2024-06-30 | $-48.99M | $53.93M | (m) | $57.83M | (m) | -90.84% |
| 2024-03-31 | $-81.38M | $25.91M | (m) | $62.95M | (m) | -314.15% |
| 2023-12-31 | $-86.42M | $26.00M | (m) | $71.84M | (m) | -332.32% |
| 2023-09-30 | $-58.58M | $34.53M | (m) | $68.38M | (m) | -169.63% |
| 2023-06-30 | $-47.11M | $48.69M | (m) | $71.91M | (m) | -96.76% |
| 2023-03-31 | $-14.62M | $82.72M | (m) | $73.31M | (m) | -17.67% |
| 2022-12-31 | $14.54M | $110.78M | (m) | $72.38M | (m) | 13.12% |
| 2022-09-30 | $27.11M | $123.92M | (m) | $73.73M | (m) | 21.88% |
| 2022-06-30 | $26.74M | $127.64M | (m) | $78.14M | (m) | 20.95% |
| 2022-03-31 | $13.33M | $108.03M | (m) | $73.42M | (m) | 12.34% |
| 2021-12-31 | $-4.60M | $85.08M | (m) | $68.74M | (m) | -5.40% |
| 2021-09-30 | $-16.57M | $67.09M | (m) | $63.51M | (m) | -24.70% |
| 2021-06-30 | $-28.34M | $47.31M | (m) | $56.52M | (m) | -59.90% |
| 2021-03-31 | $-45.16M | $27.65M | (m) | $52.78M | (m) | -163.33% |
| 2020-12-31 | $-56.82M | $16.60M | (m) | $54.51M | (m) | -342.36% |
| 2020-09-30 | $-61.49M | $11.30M | (m) | $54.57M | (m) | -544.19% |
| 2020-06-30 | $-59.55M | $6.65M | (m) | $48.71M | (m) | -895.00% |
| 2020-03-31 | $-59.42M | $6.67M | (m) | $50.11M | (m) | -891.27% |
| 2019-12-31 | $-52.45M | $6.68M | (m) | $42.74M | (m) | -785.61% |
| 2019-09-30 | $-54.38M | $926.00K | (m) | $37.85M | (m) | -5873.00% |
| 2019-06-30 | $-58.53M | $926.00K | (m) | $41.63M | (m) | -6320.84% |
| 2019-03-31 | $-61.06M | $913.00K | (m) | $43.90M | (m) | -6688.39% |
| 2018-12-31 | $-65.02M | $903.00K | (m) | $47.69M | (m) | -7200.66% |
| 2018-09-30 | $-69.80M | $17.00K | (m) | $51.05M | (m) | -410588.24% |
| 2018-06-30 | $-67.71M | $44.00K | (m) | $48.67M | (m) | -153893.18% |
| 2018-03-31 | $-64.81M | $70.00K | (m) | $45.26M | (m) | -92592.86% |
| 2017-12-31 | $-63.78M | $207.00K | (m) | $45.16M | (m) | -30813.53% |
| 2017-09-30 | $-58.37M | $3.12M | (m) | $42.58M | (m) | -1870.74% |
| 2017-06-30 | $-51.98M | $4.14M | (m) | $39.09M | (m) | -1255.28% |
| 2017-03-31 | $-42.51M | $6.13M | (m) | $34.10M | (m) | -693.26% |
| 2016-12-31 | $-34.67M | $8.08M | (m) | $29.70M | (m) | -428.92% |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $7.07M | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-25.30M | $6.01M | (m) | $22.98M | (m) | -420.96% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-15.40M | $3.04M | (m) | $10.49M | (m) | -506.55% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |